Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 8/20 | 0.61 |
| ▸ | RXRA | P19793 | 7/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474002 | 0.89 | KMT2A (0.53) | NR1H2RXRANR1H3KMT2AMEN1 | |
| SCHEMBL3472319 | 0.88 | RXRA (0.57) | NR1H2RXRANR1H3SMN1; SMN2KMT2A | |
| SCHEMBL14622602 | 0.88 | NR1H2 (0.63) | NR1H2RXRANR1H3SMN1; SMN2KMT2A | |
| SCHEMBL3475403 | 0.87 | NR1H2 (0.58) | NR1H2RXRANR1H3SMN1; SMN2KMT2A | |
| SCHEMBL3475912 | 0.82 | NR1H2 (0.58) | NR1H2RXRANR1H3SMN1; SMN2PTGS2 | |
| SCHEMBL3475558 | 0.82 | RXRA (0.66) | NR1H2RXRANR1H3KMT2AMEN1 | |
| SCHEMBL12000521 | 0.81 | KMT2A (0.66) | SMN1; SMN2KMT2AMEN1PTGS2 | |
| SCHEMBL3473709 | 0.80 | KMT2A (0.61) | SMN1; SMN2KMT2AMEN1PTGS2 | |
| SCHEMBL3473973 | 0.79 | RXRA (0.59) | NR1H2RXRANR1H3PTGS2 | |
| SCHEMBL3474296 | 0.78 | NR1H2 (0.70) | NR1H2RXRANR1H3SMN1; SMN2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885RXRA 18/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.